Seattle’s biotech industry has endured what could be called a lost decade after a number of the brightest stars of the 1990s—Immunex, Icos, Rosetta Inpharmatics, Corixa—were acquired by companies in other places that made local cutbacks. But a number of today’s Northwest biotechs, particularly Dendreon and Seattle Genetics, are emerging as globally competitive players, while potential blockbuster drug and vaccine candidates are also emerging at small startups like Alder Biopharmaceuticals, Calistoga Pharmaceuticals, and Immune Design. What needs to happen for Seattle to sustain this newfound momentum, and continue making a global impact on the life sciences industry over the coming decades?
Mitchell Gold, CEO, Dendreon
Clay Siegall, CEO, Seattle Genetics
Carol Gallagher, CEO, Calistoga Pharmaceuticals
Randy Schatzman, CEO, Alder Biopharmaceuticals
Registration: 5:15 – 6:00 pm
Program: 6:00 – 7:30 pm
Networking reception: 7:30 – 8:30 pm
Super Saver Rate (ends October 20): $75
Regular Registration: $125
Walk-in Registration: $150
Student Registration: $30
Tickets are transferable but not refundable.
To inquire about press registration, e-mail [email protected].